Talk:Polycystic ovary syndrome: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Nancy Sculerati
imported>Subpagination Bot
m (Add {{subpages}} and remove checklist (details))
 
(15 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{checklist
{{subpages}}
|                abc = Polycystic ovary syndrome
|                cat1 = Biology
|                cat2 = Health Sciences
|                cat3 =
|          cat_check = Y
|              status = 2
|        underlinked = Y
|            cleanup = Y
|                  by = [[User:Kelly Patterson|Kelly Patterson]] 11:49, 22 April 2007 (CDT)
}}


== References: with notes ==
== References: with notes ==


'''Lorenz LB. Wild RA. Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician.''' [Review] [60 refs] '''Clinical Obstetrics & Gynecology. 50(1):226-43, 2007 Mar.'''
UI: 17304038


"This review systematically addresses the evidence confirming polycystic ovary syndrome (PCOS) as a cardiovascular health threat. Literature in this area is void of long-term prospective studies to adequately evaluate outcome, but there is important evidence using surrogate markers for future development of and presence of cardiovascular disease and diabetes in women with PCOS. In addition, this article reviews the evidence regarding evaluation and management of cardiovascular risk factors in the population of women with PCOS." "Although previously identified as a cause of abnormal uterine bleeding, the term polycystic ovary syndrome (PCOS) was coined in 1935 after Stein and Leventhal reported 7 women who had amenorrhea, hirsutism, obesity, and multicystic appearing ovaries. Since then, a great deal of investigation has gone into why these women have problems of irregular menses, infertility, and hirsutism."
'''Ehrmann DA. Polycystic ovary syndrome.'''[Review] [144 refs] '''New England Journal of Medicine. 352(12):1223-36, 2005 Mar 24.  
*"Women with PCOS develop diabetes at higher rates and at younger ages than usual. The metabolic syndrome is very prevalent in women with PCOS"
UI: 15788499
'''
Several factors contribute to difficulties in the diagnosis of the polycystic ovary syndrome. Presenting signs and symptoms are heterogeneous and vary over time; in addition, a precise and uniform definition of the syndrome has been lacking. An international consensus group [3] recently proposed that the syndrome can be diagnosed after the exclusion of other medical conditions that cause irregular menstrual cycles and androgen excess (Figure 1 and Table 1) and the determination that at least two of the following are present: oligoovulation or anovulation (usually manifested as oligomenorrhea or amenorrhea), elevated levels of circulating androgens (hyperandrogenemia) or clinical manifestations of androgen excess (hyperandrogenism), and polycystic ovaries as defined by ultrasonography. [4] Women with the polycystic ovary syndrome almost always have some aberration in gonadotropin secretion as compared with women who have normal menstrual cycles. [8] However, since gonadotropin concentrations vary over the menstrual cycle and are released in a pulsatile fashion into the circulation, a single measurement of luteinizing hormone and follicle-stimulating hormone provides little diagnostic sensitivity. Thus, in routine clinical practice, abnormal gonadotropin levels (an elevated level of luteinizing hormone or an elevated ratio of luteinizing hormone to follicle-stimulating hormone) need not be documented to diagnose the polycystic ovary syndrome.


 
Chronic anovulation most often manifests as oligomenorrhea (fewer than nine menses per year) or amenorrhea. Anovulatory cycles may lead to dysfunctional uterine bleeding and decreased fertility. Cutaneous manifestations of hyperandrogenemia in the polycystic ovary syndrome include hirsutism, acne, and%2
----

Latest revision as of 09:27, 13 November 2007

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
To learn how to update the categories for this article, see here. To update categories, edit the metadata template.
 Definition:  Endocrine condition characterized by the accumulation of numerous cysts on the ovaries associated with high male hormone levels, chronic anovulation, and other metabolic disturbances, that affects approximately 5% of all women. [d] [e]
Checklist and Archives
 Workgroup categories:  Biology and Health Sciences [Editors asked to check categories]
 Talk Archive:  none  English language variant:  British English

References: with notes

Ehrmann DA. Polycystic ovary syndrome.[Review] [144 refs] New England Journal of Medicine. 352(12):1223-36, 2005 Mar 24. UI: 15788499 Several factors contribute to difficulties in the diagnosis of the polycystic ovary syndrome. Presenting signs and symptoms are heterogeneous and vary over time; in addition, a precise and uniform definition of the syndrome has been lacking. An international consensus group [3] recently proposed that the syndrome can be diagnosed after the exclusion of other medical conditions that cause irregular menstrual cycles and androgen excess (Figure 1 and Table 1) and the determination that at least two of the following are present: oligoovulation or anovulation (usually manifested as oligomenorrhea or amenorrhea), elevated levels of circulating androgens (hyperandrogenemia) or clinical manifestations of androgen excess (hyperandrogenism), and polycystic ovaries as defined by ultrasonography. [4] Women with the polycystic ovary syndrome almost always have some aberration in gonadotropin secretion as compared with women who have normal menstrual cycles. [8] However, since gonadotropin concentrations vary over the menstrual cycle and are released in a pulsatile fashion into the circulation, a single measurement of luteinizing hormone and follicle-stimulating hormone provides little diagnostic sensitivity. Thus, in routine clinical practice, abnormal gonadotropin levels (an elevated level of luteinizing hormone or an elevated ratio of luteinizing hormone to follicle-stimulating hormone) need not be documented to diagnose the polycystic ovary syndrome.

Chronic anovulation most often manifests as oligomenorrhea (fewer than nine menses per year) or amenorrhea. Anovulatory cycles may lead to dysfunctional uterine bleeding and decreased fertility. Cutaneous manifestations of hyperandrogenemia in the polycystic ovary syndrome include hirsutism, acne, and%2

Retrieved from "https://citizendium.org/wiki/index.php?title=Talk:Polycystic_ovary_syndrome&oldid=25074"